Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Seiler

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Oncotarget|September 9, 2017
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patientsMohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, et al.
Molecular Cancer Therapeutics|September 29, 2018
Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder CancerTilman Todenhöfer, Roland Seiler, Craig Stewart, et al.
European Urology Oncology|April 25, 2019
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder CancerStephen B Williams, Hogan K Hudgins, Mohamed D Ray-Zack, et al.
Surgical Oncology|September 6, 2020
The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working groupPhilipp Gild, Malte W Vetterlein, Roland Seiler, et al.
European Urology|March 12, 2023
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
European Urology Focus|December 19, 2018
Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical OutcomesCharlotte S Voskuilen, Roland Seiler, Michael Rink, et al.
Urologic Oncology|September 20, 2016
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelinesBernd J Schmitz-Dräger, Eva C Kuckuck, Tahlita C M Zuiverloon, et al.
European Urology|August 14, 2022
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerAlberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
Genome Medicine|October 18, 2019
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosisJoep J de Jong, Yang Liu, A Gordon Robertson, et al.
The American Journal of Surgical Pathology|September 17, 2019
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaCharlotte S Voskuilen, Htoo Zarni Oo, Vera Genitsch, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Oncotarget|September 9, 2017
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patientsMohammed Alshalalfa, Gerald W Verhaegh, Ewan A Gibb, et al.
Molecular Cancer Therapeutics|September 29, 2018
Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder CancerTilman Todenhöfer, Roland Seiler, Craig Stewart, et al.
European Urology Oncology|April 25, 2019
Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder CancerStephen B Williams, Hogan K Hudgins, Mohamed D Ray-Zack, et al.
Surgical Oncology|September 6, 2020
The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working groupPhilipp Gild, Malte W Vetterlein, Roland Seiler, et al.
European Urology|March 12, 2023
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17]Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
European Urology Focus|December 19, 2018
Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical OutcomesCharlotte S Voskuilen, Roland Seiler, Michael Rink, et al.
Urologic Oncology|September 20, 2016
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelinesBernd J Schmitz-Dräger, Eva C Kuckuck, Tahlita C M Zuiverloon, et al.
European Urology|August 14, 2022
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerAlberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.
Genome Medicine|October 18, 2019
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosisJoep J de Jong, Yang Liu, A Gordon Robertson, et al.
The American Journal of Surgical Pathology|September 17, 2019
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaCharlotte S Voskuilen, Htoo Zarni Oo, Vera Genitsch, et al.
Pageof 14